Similarly, immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, can enhance anti-tumor immunity by reversing T-cell exhaustion, yet their overall response rates remain low, with only a subset of patients experiencing meaningful clinical benefits, particularly in recurrent or metastatic cervical cancer (29). The gene discussed is CTLA4; the disease is neoplasm.